HUTCHMED (China) (HCM) Other Non-Current Liabilities (2015 - 2026)
HUTCHMED (China) (HCM) posted quarterly Other Non-Current Liabilities of $97.9 million for Q2 2026, up 5.2% year-over-year from $93.0 million in Q2 2025, and up 641.24% quarter-over-quarter from $13.2 million in Q4 2025.
HUTCHMED (China) (HCM) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Other Non-Current Liabilities for 12 consecutive years, with $97.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 5.2% year-over-year to $97.9 million; the TTM figure through Jun 2026 stood at $97.9 million (up 5.2% YoY), while the FY2025 annual figure was $91.4 million, up 2066.72% from the prior year.
- Other Non-Current Liabilities advanced to $97.9 million in Q2 2026 per HCM's latest filing, from $13.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.8 billion in Q4 2023 and bottomed at $2.9 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $345.5 million across 5 years, with a median of $19.3 million in 2024.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 88088.42% — and 2024, when it tumbled 99.9%.
- HUTCHMED (China)'s Other Non-Current Liabilities stood at $3.2 million in 2022, then surged by 88088.42% to $2.8 billion in 2023, then slumped by 99.9% to $2.9 million in 2024, then jumped by 358.53% to $13.2 million in 2025, then surged by 641.24% to $97.9 million in 2026.
- Business Quant data shows HCM's Other Non-Current Liabilities at $97.9 million in Q2 2026, $13.2 million in Q4 2025, and $93.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | HUTCHMED (China) | 2.19 Bn | 2.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 97.88 Mn |
| Dec 31, 2025 | 13.21 Mn |
| Jun 30, 2025 | 93.04 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Jun 30, 2024 | 19.31 Mn |
| Dec 31, 2023 | 2.84 Bn |
| Jun 30, 2023 | 19.29 Mn |
| Dec 31, 2022 | 3.22 Mn |
| Jun 30, 2022 | 20.21 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Jun 30, 2021 | 5.52 Mn |
| Mar 31, 2021 | 6.81 Mn |
| Dec 31, 2020 | 8.78 Mn |
| Jun 30, 2020 | 9.01 Mn |
| Dec 31, 2019 | 5.96 Mn |
| Sep 30, 2019 | 7.46 Mn |
| Jun 30, 2019 | 7.86 Mn |
| Mar 31, 2019 | 8.33 Mn |
| Dec 31, 2018 | 2.40 Mn |
| Jun 30, 2018 | 2.85 Mn |